Immupharma PLC Notice of AGM and posting of Report & Accounts (5047N)
May 21 2020 - 2:00AM
UK Regulatory
TIDMIMM
RNS Number : 5047N
Immupharma PLC
21 May 2020
RNS: RELEASE 21 MAY 2020
ImmuPharma PLC
("ImmuPharma" or the "Company")
Notice of AGM and posting of Report & Accounts
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM), the
specialist drug discovery and development company, confirms that
the Annual Report and Accounts for the year ended 31 December 2019,
and the Notice of Annual General Meeting has been posted to
shareholders.
These documents are available, in electronic form, for download
on the Company's website www.immupharma.co.uk .
ImmuPharma's Annual General Meeting (AGM) will be held on
Thursday, 18 June 2020 @ 10.30am (BST) at: 50 Broadway, London SW1H
0RG.
COVID-19 Guidance
We note the current issues surrounding COVID-19 (coronavirus)
and the rapidly developing public health guidance in the UK at the
time of writing. This includes the stringent requirements announced
on 23 March 2020, which require UK nationals to stay at home except
in tightly defined circumstances (which do not include attending an
AGM), the social distancing and shielding guidance for those over
the age of 70 or with underlying medical conditions, and the ban on
all non-essential travel. The health and safety of our shareholders
and colleagues is always our utmost priority.
As it is no longer possible to hold the AGM in the way that the
Board had planned, we cannot allow shareholders to attend in
person. Any shareholders attempting to gain access to the AGM will
be excluded from the meeting on grounds of public safety. In the
light of the above, we strongly encourage you to consider ensuring
your vote is counted by submission of the proxy by post as detailed
in the Notice of Annual General Meeting.
Ends
For further information please contact:
ImmuPharma PLC ( www.immupharma.com )
Tim McCarthy, Chairman + 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0) 203 36 8 8974
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes +44 (0) 203 815 8880
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
4Reliance (Euronext Growth Listing Sponsor) +32 (0) 2 747 02 60
Jean-Charles Snoy
Degroof Petercam (Liquidity Provider) +32 (0) 2 287 95 34
Erik De Clippel
Backstage Communication
Olivier Duquaine +32 (0) 477 504 784
Gunther De Backer +32 (0) 475 903 909
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases, metabolic diseases,
anti-infectives and cancer. The lead program, Lupuzor(TM), is a
first-in class autophagy immunomodulator which is in Phase III for
the treatment of lupus and preclinical analysis suggest therapeutic
activity for many other autoimmune diseases that share the same
autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals
signed on 29 November 2019, an exclusive licence and development
agreement and trademark agreement for Lupuzor(TM) to fund a new
international Phase III trial for Lupuzor(TM) and commercialise in
the US. For additional information about ImmuPharma please visit
www.immupharma.com . ImmuPharma's LEI (Legal Entity Identifier)
code: 213800VZKGHXC7VUS895.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCAMMMTMTATBPM
(END) Dow Jones Newswires
May 21, 2020 02:00 ET (06:00 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024